NEW YORK and MELBOURNE, Australia, May 06, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the third quarter/nine months ended March 31 2016 and provide a corporate update beginning at 7:00 pm Eastern Time on Monday, May 9 2016 and 9:00 am Australian Eastern Standard Time on Tuesday, May 10 2016.
To access the call, dial 1 855 881 1339 (toll-free US), 1 800 558 698 (toll-free Australia) or 61 2 9007 3187 (outside of the US and Australia).
The conference identification code is 762609.
The live webcast can be accessed via: http://webcasting.brrmedia.com/broadcast/5652364ab9ebca62060cb159
The conference call will be accompanied by a slide presentation. Please log in approximately 15 minutes prior to the scheduled start time.
The archived webcast will be available in the Events and Presentations section of the Investor page on the Company’s website – www.mesoblast.com
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
For further information, please contact: Julie Meldrum Global Head, Corporate Communications Mesoblast Limited T: +61 3 9639 6036 E: email@example.com Michael Schuster Head, Investor Relations Mesoblast Limited T: +1 212 880 2060 E: firstname.lastname@example.org